Phase IVEnrolling✓ PAG Endorsed by National MS Society Remote Available

Natalizumab Extended Interval Dosing in Relapsing-Remitting Multiple Sclerosis

Biogen·NCT05489211·Multiple Sclerosis

Duration

24 months

Cost

Free to Patients

Phase

Phase IV

Closes

Aug 2025

About This Trial

Comparing standard 4-week vs extended 6-week natalizumab dosing intervals in RRMS patients.

Trial Locations

Boston, MA

Cleveland, OH

Seattle, WA

Remote participation available, some or all visits can be done from home.

Eligibility & What to Expect

Condition focus: Multiple Sclerosis

Available in: US

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Patient Advocacy Endorsed

National MS Society endorses this trial

This trial has been reviewed and endorsed by National MS Society. PAG endorsement means patient advocates have evaluated the trial design, risk-benefit profile, and patient-friendliness of this study.

Trial Summary

NCT NumberNCT05489211

SponsorBiogen

PhasePhase IV

Duration24 months

ClosesAug 2025

ConditionMultiple Sclerosis